|
1.
|
|
|
2.
|
|
11 p, 1.8 MB |
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks : A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Costanzo, Antonio (Humanitas Clinical and Research Center IRCCS) ;
de Jong, Elke M. G. J. (Radboud University Medical Center) ;
Torres, Tiago (University of Porto) ;
Warren, Richard B. (The University of Manchester) ;
Wapenaar, Robert (Janssen-Cilag BV (Breda, Països Baixos)) ;
Wegner, Sven (Janssen-Cilag GmbH (Neuss, Alemanya)) ;
Gorecki, Patricia (Janssen-Cilag Ltd (High Wycombe, Regne Unit)) ;
Gramiccia, Talia (Janssen-Cilag SpA (Milà, Itàlia)) ;
Jazra, Maria (Janssen-Cilag (París, França)) ;
Buyze, Jozefien (Janssen Pharmaceutica NV (Beerse, Bèlgica)) ;
Conrad, Curdin (University of Lausanne) ;
Universitat Autònoma de Barcelona
Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices. [...]
2023 -  10.1007/s40257-023-00816-1
American Journal of Clinical Dermatology, Vol. 25 (october 2023) , p. 315-325
|
|
|
3.
|
|
10 p, 673.5 KB |
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors : A Retrospective, Multinational, Multicentre Study
/
Torres, Tiago (University of Porto, Portugal) ;
Chiricozzi, Andrea (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Lé, Ana Maria (Centro Académico Clínico ICBAS - CHP, Porto, Portugal) ;
Marzano, Angelo Valerio (Università degli Studi di Milano, Italy) ;
Dapavo, Paolo (University of Turin, Italy) ;
Dauden, Esteban (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid) ;
Carrascosa, Jόse-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Duarte, Gleison (Instituto Bahiano de Imunoterapias-IBIS, Salvador, Brazil) ;
Carvalho, André V. E. (Hospital Moinhos de Vento, Porto Alegre, Brazil) ;
Romiti, Ricardo (University of São Paulo, Brazil) ;
Rompoti, Natalia (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Teixeira, Laetitia (Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal) ;
Abreu, Miguel (University of Porto, Portugal) ;
Ippoliti, Elena (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Maronese, Carlo Alberto (Università degli Studi di Milano, Italy) ;
Llamas-Velasco, Mar (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP)) ;
Vilarrasa-Rull, Eva (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
del Alcázar, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Daponte, Athina-Ioanna (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Papoutsaki, Marina (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Carugno, Andrea (ASST Papa Giovanni XXIII, Bergamo, Italy) ;
Bellinato, Francesco (University Hospital of Verona, Italy) ;
Gisondi, Paolo (University Hospital of Verona, Italy) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. [...]
2024 - 10.1007/s40257-024-00845-4
American Journal of Clinical Dermatology, Vol. 25, Num. 2 (march 2024) , p. 333-342
|
|
|
4.
|
|
|
5.
|
|
16 p, 1.2 MB |
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab : A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) ;
Bianchi, Luca (U.O.S.D. di Dermatologia Fondazione PTV Policlinico Tor Vergata, Rome, Italy) ;
Khemis, Abdallah (Polyclinique Saint George, Groupe KANTYS, Nice, France) ;
Maul, Julia-Tatjana (University of Zürich) ;
Tsianakas, Athanasios (Fachklinik Bad Bentheim, Bad Bentheim, Germany) ;
Schempp, Christoph M. (University of Freiburg, Germany) ;
Petersen, Kim (LEO Pharma A/S, Ballerup, Denmark) ;
Noergaard, Mia M. (LEO Pharma A/S, Ballerup, Denmark) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians' choice of treatment. [...]
2024 - 10.1007/s13555-023-01092-x
Dermatology and Therapy, Vol. 14 (february 2024) , p. 453-468
|
|
|
6.
|
|
2 p, 292.1 KB |
Corrigendum : The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published. [...]
2023 - 10.3389/fimmu.2023.1332177
Frontiers in immunology, Vol. 14 (2023) , p. 1332177
|
|
|
7.
|
|
9 p, 748.2 KB |
Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain : A Multidimensional Evaluation
/
Zozaya, Néboa (Universidad de Las Palmas de Gran Canaria) ;
Villoro, Renata (Weber Foundation) ;
Abdalla, Fernando (Weber Economía y Salud) ;
Alfonso Zamora, Santiago (Psoriasis and Psoriatic Arthritis Patient and Family Association) ;
Balea Filgueiras, Jesús (Complejo Hospitalario Universitario de Ferrol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Delgado Sánchez, Olga (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València)) ;
García-Ruiz, Antonio (Instituto de Investigación Biomédica de Málaga) ;
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid)) ;
Manfredi, Antonio (Psoriasis and Psoriatic Arthritis Patient and Family Association) ;
Martínez Olmos, José (Escuela Andaluza de Salud Pública) ;
Morales de los Ríos, Paloma (Hospital General Universitario Gregorio Marañón) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Ros Abarca, Sandra (Institut d'Investigació Biomèdica Sant Pau) ;
Hidalgo, Álvaro (Universidad de Castilla-La Mancha) ;
Universitat Autònoma de Barcelona
Psoriasis is a chronic, systemic inflammatory disease that affects the skin, with a high impact on patients' quality of life. The aim of this study was to identify and determine the relative importance of unmet needs in the management of moderate-to-severe psoriasis in Spain, from a multi-stakeholder perspective. [...]
2022 - 10.2340/actadv.v102.583
Acta dermato-venereologica, Vol. 102 (2022) , p. adv00678
|
|
|
8.
|
|
15 p, 3.0 MB |
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
/
Zozaya, Néboa (Universidad de Las Palmas de Gran Canaria) ;
Abdalla, Fernando (Weber (Madrid)) ;
Alfonso Zamora, Santiago (Psoriasis and Psoriatic Arthritis Patient and Family Association) ;
Balea Filgueiras, Jesus (Complejo Hospitalario Universitario de Ferrol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Delgado Sánchez, Olga (Hospital Universitari Son Espases)) ;
Dolz Sinisterra, Francisco (Hospital Universitari Doctor Peset (València)) ;
García-Ruiz, Antonio (Instituto de Investigación Biomédica de Málaga) ;
Herranz Pinto, Pedro (Hospital Universitario La Paz (Madrid)) ;
Manfredi, Antonio (Psoriasis and Psoriatic Arthritis Patient and Family Association) ;
Martínez Olmos, José (Escuela Andaluza de Salud Pública (Granada, Andalusia)) ;
Morales de Los Ríos Luna, Paloma (Hospital General Universitario Gregorio Marañón) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Ros Abarca, Sandra (Institut d'Investigació Biomèdica Sant Pau) ;
Hidalgo-Vega, Álvaro (Universidad de Castilla-La Mancha) ;
Universitat Autònoma de Barcelona
Background: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. [...]
2022 - 10.1080/14737167.2022.2063842
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22 Núm. 6 (2022) , p. 941-953
|
|
|
9.
|
|
|
10.
|
|
14 p, 4.2 MB |
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-κB) pathway. [...]
2023 - 10.3389/fimmu.2023.1191782
Frontiers in immunology, Vol. 14 (august 2023)
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
